---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-012763"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2022-01-20T23:59:59+00:00"
generated_at: "2026-06-27T16:47:08.023271+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience enters manufacturing agreement with Fresenius Kabi for Fyarro

## Summary
- Fresenius Kabi to manufacture Fyarro (sirolimus protein-bound) for Aadi under a purchase-order basis.
- Agreement effective through Dec 31, 2022; covers clinical and commercial supply for US and Canada.
- Aadi has minimum purchase obligations; failure triggers additional payment to Fresenius Kabi.
- Price fixed but subject to increase under specified circumstances; includes labeling/packaging services.

## SEC filing metadata
- accession: 0001193125-22-012763
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2022-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312522012763/0001193125-22-012763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312522012763/d295801d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-012763
- JSON: https://secwatch.observer/filing/0001193125-22-012763.json
- Plain text: https://secwatch.observer/filing/0001193125-22-012763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.